Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder.

McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, White KG, Brady KT.

Am J Addict. 2010 Nov-Dec;19(6):481-9. doi: 10.1111/j.1521-0391.2010.00076.x. Epub 2010 Sep 21.

PMID:
20958842
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.

Durell TM, Adler LA, Williams DW, Deldar A, McGough JJ, Glaser PE, Rubin RL, Pigott TA, Sarkis EH, Fox BK.

J Clin Psychopharmacol. 2013 Feb;33(1):45-54. doi: 10.1097/JCP.0b013e31827d8a23. Erratum in: J Clin Psychopharmacol. 2014 Aug;34(4):542-3.

PMID:
23277268
[PubMed - indexed for MEDLINE]
3.

Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.

Simpson D, Plosker GL.

Drugs. 2004;64(2):205-22. Review.

PMID:
14717619
[PubMed - indexed for MEDLINE]
4.

Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.

Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM.

J Child Adolesc Psychopharmacol. 2011 Apr;21(2):97-110. doi: 10.1089/cap.2009.0111. Epub 2011 Apr 13.

PMID:
21488751
[PubMed - indexed for MEDLINE]
5.

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.

Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz PT, Williams DW, Kelsey D.

J Clin Psychopharmacol. 2009 Feb;29(1):44-50. doi: 10.1097/JCP.0b013e318192e4a0.

PMID:
19142107
[PubMed - indexed for MEDLINE]
6.

A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.

Harfterkamp M, van de Loo-Neus G, Minderaa RB, van der Gaag RJ, Escobar R, Schacht A, Pamulapati S, Buitelaar JK, Hoekstra PJ.

J Am Acad Child Adolesc Psychiatry. 2012 Jul;51(7):733-41. doi: 10.1016/j.jaac.2012.04.011. Epub 2012 May 25.

PMID:
22721596
[PubMed - indexed for MEDLINE]
7.

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.

Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L; Atomoxetine ADHD/ODD Study Group.

Pediatrics. 2008 Feb;121(2):e314-20. doi: 10.1542/peds.2006-1880. Erratum in: Pediatrics.2008 Jul;122(1): 227.

PMID:
18245404
[PubMed - indexed for MEDLINE]
Free Article
8.

Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.

Simpson D, Plosker GL.

CNS Drugs. 2004;18(6):397-401. Review.

PMID:
15089111
[PubMed - indexed for MEDLINE]
9.

Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.

Wietecha L, Williams D, Shaywitz S, Shaywitz B, Hooper SR, Wigal SB, Dunn D, McBurnett K.

J Child Adolesc Psychopharmacol. 2013 Nov;23(9):605-13. doi: 10.1089/cap.2013.0054. Epub 2013 Nov 9.

PMID:
24206099
[PubMed - indexed for MEDLINE]
10.

Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.

Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, García-Polavieja MJ, Gilaberte I, Escobar R.

Curr Med Res Opin. 2009 Nov;25(11):2745-54. doi: 10.1185/03007990903316152.

PMID:
19785510
[PubMed - indexed for MEDLINE]
11.

Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia.

Martenyi F, Zavadenko NN, Jarkova NB, Yarosh AA, Soldatenkova VO, Bardenstein LM, Kozlova IA, Neznanov NG, Maslova OI, Petrukhin AS, Sukchotina NK, Zykov VP.

Eur Child Adolesc Psychiatry. 2010 Jan;19(1):57-66. doi: 10.1007/s00787-009-0042-7. Epub 2009 Jul 1.

PMID:
19568826
[PubMed - indexed for MEDLINE]
12.

Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.

Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, Renard D, Brady KT, Trzepacz PT, Schuh LM, Ahrbecker LM, Levine LR; Atomoxetine ADHD/SUD Study Group.

Drug Alcohol Depend. 2008 Jul 1;96(1-2):145-54. doi: 10.1016/j.drugalcdep.2008.02.009. Epub 2008 Apr 9.

PMID:
18403134
[PubMed - indexed for MEDLINE]
13.

Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.

Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C; 31001074-ATT2001 Study Investigators.

CNS Drugs. 2012 May 1;26(5):421-34. doi: 10.2165/11631990-000000000-00000.

PMID:
22519922
[PubMed - indexed for MEDLINE]
14.

Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine.

Wilens TE, Adler LA, Tanaka Y, Xiao F, D'Souza DN, Gutkin SW, Upadhyaya HP.

Curr Med Res Opin. 2011 Dec;27(12):2309-20. doi: 10.1185/03007995.2011.628648. Epub 2011 Oct 27.

PMID:
22029549
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.

Gau SS, Huang YS, Soong WT, Chou MC, Chou WJ, Shang CY, Tseng WL, Allen AJ, Lee P.

J Child Adolesc Psychopharmacol. 2007 Aug;17(4):447-60.

PMID:
17822340
[PubMed - indexed for MEDLINE]
16.

Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.

Harfterkamp M, Buitelaar JK, Minderaa RB, van de Loo-Neus G, van der Gaag RJ, Hoekstra PJ.

J Child Adolesc Psychopharmacol. 2013 Apr;23(3):194-9. doi: 10.1089/cap.2012.0012. Epub 2013 Apr 11.

PMID:
23578015
[PubMed - indexed for MEDLINE]
17.

Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.

Adler LA, Wilens T, Zhang S, Dittmann RW, D'Souza DN, Schuh L, Durell TM.

Clin Ther. 2012 Feb;34(2):363-73. doi: 10.1016/j.clinthera.2011.12.015. Epub 2012 Jan 27.

PMID:
22285724
[PubMed - indexed for MEDLINE]
18.

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.

Cheng JY, Chen RY, Ko JS, Ng EM.

Psychopharmacology (Berl). 2007 Oct;194(2):197-209. Epub 2007 Jun 16.

PMID:
17572882
[PubMed - indexed for MEDLINE]
19.

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.

Pediatrics. 2004 Jul;114(1):e1-8.

PMID:
15231966
[PubMed - indexed for MEDLINE]
20.

Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.

Hazell P, Becker K, Nikkanen EA, Trzepacz PT, Tanaka Y, Tabas L, D'Souza DN, Witcher J, Long A, Ponsler G, Dittmann RW.

Atten Defic Hyperact Disord. 2009 Dec;1(2):201-10. doi: 10.1007/s12402-009-0012-4. Epub 2009 Sep 23.

PMID:
20234828
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk